Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3371
Name chondrosarcoma
Definition A bone sarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage.
Source DiseaseOntology.org
Alt Ids DOID:3370
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma chondrosarcoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 mutant Dasatinib chondrosarcoma resistant detail...
IDH1 R132C Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132G Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132L Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 R132S Ivosidenib chondrosarcoma predicted - sensitive detail...
IDH1 act mut Ivosidenib chondrosarcoma sensitive detail...
MLH1 negative Pembrolizumab chondrosarcoma sensitive detail...
PMS2 negative Pembrolizumab chondrosarcoma sensitive detail...
MSH2 negative Pembrolizumab chondrosarcoma sensitive detail...
MSH6 negative Pembrolizumab chondrosarcoma sensitive detail...
IDH1 R132S Olaparib chondrosarcoma predicted - sensitive detail...
IDH1 R132C Olaparib chondrosarcoma predicted - sensitive detail...
IDH2 R172S Ceralasertib + Olaparib chondrosarcoma sensitive detail...
IDH1 act mut Olutasidenib chondrosarcoma predicted - sensitive detail...
CD274 over exp Pembrolizumab chondrosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Recruiting ITA | ESP 1
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed USA | FRA | ESP 3
NCT04040205 Phase II Abemaciclib Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Recruiting USA 1
NCT04278781 Phase II Ivosidenib AG-120 in People With IDH1 Mutant Chondrosarcoma Recruiting USA 0
NCT04340843 Phase II Belinostat + Guadecitabine Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Suspended USA 0
NCT04458922 Phase II Atezolizumab Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma Active, not recruiting USA | CAN 0
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Recruiting USA | FRA | ESP 6
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Recruiting USA 0
NCT04950075 Phase II INBRX-109 Study of INBRX-109 in Conventional Chondrosarcoma Recruiting USA | ITA | FRA | ESP | DEU 3
NCT05039801 Phase I IACS-6274 IACS-6274 + Pembrolizumab IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | FRA | ESP 0